China has become one of the world’s most important biopharma innovation hubs, reshaping how companies source assets, build development capabilities and pursue global growth. This whitepaper explores the next phase of cross-border collaboration, revealing what deal structures tell us about buyer confidence and how stronger market and competitive intelligence can support smarter decisions.
Key takeaways
- Understand why biopharma deals are shifting from individual pipeline assets towards broader development platforms and capabilities.
- Discover what upfront payments and milestone structures reveal about asset value, buyer confidence and investment risk.
- Explore the opportunities and challenges facing Western companies entering China and Chinese biopharma businesses expanding globally.
- Learn how market and competitive intelligence can strengthen partner identification, opportunity assessment and deal strategy.
- Identify the capabilities businesses need to become more agile, informed and “China-compatible.”
“China Biotech and Pharma is one of the biggest innovation stories of the decade.”
Download the whitepaper
Authors: Peter Barschdorff, Hannah Hans, Sarah Nightingale, and Nancy Wang.
